Emergent BioSolutions Inc.
EBS· NYSE
EBSEmergent BioSolutions Inc.
Filed Aug 7, 2024 · 10-Q · 38 days after period end · 0001367644-24-000147
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $254.70M | $337.90M | $242.60M | $397.50M |
| Net Income | -$283.10M | -$261.40M | -$52.90M | -$500.00K |
| EPS Diluted | -$5.38 | -$5.16 | -$1.06 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end
